Having trouble accessing articles? Reset your cache.

STA-9090: Phase II amended

Synta amended an ongoing, open-label Phase II trial evaluating intravenous STA-9090 given weekly for 3 weeks as part of

Read the full 194 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE